Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M. Gravis G, et al. Among authors: krakowski i. Lancet Oncol. 2013 Feb;14(2):149-58. doi: 10.1016/S1470-2045(12)70560-0. Epub 2013 Jan 8. Lancet Oncol. 2013. PMID: 23306100 Clinical Trial.
[Randomized placebo trial of myeloprotection with goralatide in patients with squamous cell carcinoma of the upper respiratory and digestive tracts or esophagus, treated with a carboplatin-fluorouracil combination].
Cappelaere P, Hecquet B, Rolland F, Meeus L, Domenge C, Krakowski I, De Gislain C, Chauvergne J, Dufour-Esquerré F, Carde P. Cappelaere P, et al. Among authors: krakowski i. Bull Cancer. 1995 Sep;82(9):732-7. Bull Cancer. 1995. PMID: 8535033 Clinical Trial. French.
A multicentre phase II study of docetaxel 75 mg m-2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. European Organization for Research and Treatment of Cancer.
Dieras V, Chevallier B, Kerbrat P, Krakowski I, Roche H, Misset JL, Lentz MA, Azli N, Murawsky M, Riva A, Pouillart P, Fumoleau P. Dieras V, et al. Among authors: krakowski i. Br J Cancer. 1996 Aug;74(4):650-6. doi: 10.1038/bjc.1996.416. Br J Cancer. 1996. PMID: 8761385 Free PMC article. Clinical Trial.
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E, Tadrist Z, Pavlovitch JM, Hauteville D, Mejean A, Azagury M, Mayeur D, Lucas V, Krakowski I, Larregain-Fournier D, Abourachid H, Andrieu JM, Chastang C. Tourani JM, et al. Among authors: krakowski i. J Clin Oncol. 1998 Jul;16(7):2505-13. doi: 10.1200/JCO.1998.16.7.2505. J Clin Oncol. 1998. PMID: 9667271 Clinical Trial.
Abiraterone and increased survival in metastatic prostate cancer.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators. de Bono JS, et al. N Engl J Med. 2011 May 26;364(21):1995-2005. doi: 10.1056/NEJMoa1014618. N Engl J Med. 2011. PMID: 21612468 Free PMC article. Clinical Trial.
A phase III trial of docetaxel-estramustine in high-risk localised prostate cancer: a planned analysis of response, toxicity and quality of life in the GETUG 12 trial.
Fizazi K, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houedé N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Lagrange JL, Chinet-Charrot P, Linassier C, Deplanque G, Beuzeboc P, Geneve J, Davin JL, Tournay E, Culine S. Fizazi K, et al. Among authors: krakowski i. Eur J Cancer. 2012 Jan;48(2):209-17. doi: 10.1016/j.ejca.2011.10.015. Epub 2011 Nov 24. Eur J Cancer. 2012. PMID: 22119204 Clinical Trial.
Patients' self-assessment versus investigators' evaluation in a phase III trial in non-castrate metastatic prostate cancer (GETUG-AFU 15).
Gravis G, Marino P, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Fizazi K. Gravis G, et al. Among authors: krakowski i. Eur J Cancer. 2014 Mar;50(5):953-62. doi: 10.1016/j.ejca.2013.11.034. Epub 2014 Jan 11. Eur J Cancer. 2014. PMID: 24424105 Clinical Trial.
Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G, Boher JM, Fizazi K, Joly F, Priou F, Marino P, Latorzeff I, Delva R, Krakowski I, Laguerre B, Walz J, Rolland F, Théodore C, Deplanque G, Ferrero JM, Pouessel D, Mourey L, Beuzeboc P, Zanetta S, Habibian M, Berdah JF, Dauba J, Baciuchka M, Platini C, Linassier C, Labourey JL, Machiels JP, El Kouri C, Ravaud A, Suc E, Eymard JC, Hasbini A, Bousquet G, Soulie M, Oudard S. Gravis G, et al. Among authors: krakowski i. Eur Urol. 2015 Aug;68(2):196-204. doi: 10.1016/j.eururo.2014.09.022. Epub 2014 Sep 30. Eur Urol. 2015. PMID: 25277272 Clinical Trial.
Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K, Faivre L, Lesaunier F, Delva R, Gravis G, Rolland F, Priou F, Ferrero JM, Houede N, Mourey L, Theodore C, Krakowski I, Berdah JF, Baciuchka M, Laguerre B, Fléchon A, Ravaud A, Cojean-Zelek I, Oudard S, Labourey JL, Chinet-Charrot P, Legouffe E, Lagrange JL, Linassier C, Deplanque G, Beuzeboc P, Davin JL, Martin AL, Habibian M, Laplanche A, Culine S. Fizazi K, et al. Among authors: krakowski i. Lancet Oncol. 2015 Jul;16(7):787-94. doi: 10.1016/S1470-2045(15)00011-X. Epub 2015 May 28. Lancet Oncol. 2015. PMID: 26028518 Clinical Trial.
85 results